Perinatal EvidenceCompass
Prepopulated workbenchMED-285

Nonprescription/emerging psychoactive — psychedelic/entactogen

Lysergic acid diethylamide

Investigational psychedelic-assisted treatment and nonmedical exposure

Brand / product examples: LSD

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Lysergic acid diethylamide
Entity type
controlled substance/research intervention
Active component(s)
Lysergic acid diethylamide
Formulation / route / interval
Oral; formulation varies
Attachment entry
LSD
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
LSD = lysergic acid diethylamide
Inventory verification confidence
High — direct status-changing or product-specific primary source

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

1 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-062Provisional public source

Old small studies and case reports of LSD do not establish a congenital-defect pattern, but pregnancy, neurodevelopment and lactation evidence remain inadequate.

Public-source certainty descriptor
Very low
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
LSD exposure versus no exposure
Effect or numbers carried forward

No reliable causal estimate

Limitations

Historical exposure ascertainment and co-use are poor; acute trauma, panic or psychosis may dominate risk

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending